Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there wa...